Effects of cannabis

Turnbridge® is in-network with Optum

Retrieved on: 
Monday, November 14, 2022
Academy, Optum, Adult, Effects of cannabis, Yale school, Cigna, Adolescence, Community, American Academy of Child and Adolescent Psychiatry, Woman, Blue Cross Blue Shield Association, Aetna, Substance use disorder, Yale School of Medicine, Association, THC, Man, Mental health, Young adult, UnitedHealth Group, Child, Ontario Hospital Association, Psychiatry, Program, Binge drinking, Mental, Futures studies, Pediatrics (journal), Children's Hospital Association, American Academy, Health insurance, Pharmaceutical industry, Medicine, Residential care, Nightclub, Turnbridge, Pediatrics, HAVEN

NEW HAVEN, Conn., Nov. 14, 2022 /PRNewswire/ -- Turnbridge, the preeminent adolescent, teen, and emerging adult behavioral healthcare provider, is now in-network with United Healthcare, Optum, and affiliated plans.

Key Points: 
  • NEW HAVEN, Conn., Nov. 14, 2022 /PRNewswire/ -- Turnbridge, the preeminent adolescent, teen, and emerging adult behavioral healthcare provider, is now in-network with United Healthcare, Optum, and affiliated plans.
  • Optum and Blue Cross Blue Shield plans, and Cigna and Aetna plans with out-of-network benefits cover the entire cost of treatment at Turnbridge adolescent residential treatment programs.
  • These plans also cover a significant portion of Turnbridge young men's, young women's, and adolescent extended care program costs.
  • The ability for Optum members to access Turnbridge makes a vitally important difference in their ability to get the help they need to make a real and lasting impact," says Turnbridge Executive Vice President Jamie Hazelton.

Global Medical Cannabis Market (2021 to 2026) - Industry Trends, Share, Size, Growth, Opportunity and Forecasts - ResearchAndMarkets.com

Retrieved on: 
Monday, September 6, 2021
Alternative Medicine, Health, Medicinal plants, Health sciences, Psychoactive drugs, Branches of biology, Herbalism, Entheogens, Euphoriants, Cannabis smoking, Cannabis, Medical cannabis, Effects of cannabis, Medical cannabis research

Cannabis is a psychoactive drug that is derived from the cannabis plant of the Cannabaceae family.

Key Points: 
  • Cannabis is a psychoactive drug that is derived from the cannabis plant of the Cannabaceae family.
  • Owing to its therapeutic benefits, cannabis has been approved for medical use in numerous countries, with varying degrees of legal restrictions.
  • Clinical trials, research and development (R&D) activities and commercialization of cannabis-based indications are further expected to catalyze the growth of the market.
  • As a result, increasing disposable incomes are projected to create a positive impact on the demand for medical cannabis.

RIV Capital Sets Date for First Quarter Fiscal Year 2022 Financial Results

Retrieved on: 
Tuesday, August 3, 2021
Cannabis smoking, Health sciences, Herbalism, Medicinal plants, Psychoactive drugs, Medicine, Cannabis, Entheogens, Medical cannabis, Effects of cannabis, Government procurement in the United States

RIV Capital is an investment and acquisition company specializing in cannabis with a portfolio of 13 companies across various segments of the cannabis value chain.

Key Points: 
  • RIV Capital is an investment and acquisition company specializing in cannabis with a portfolio of 13 companies across various segments of the cannabis value chain.
  • We believe that bringing together people, capital, and ideas raises the potential of the entire cannabis industry.
  • Although RIV Capital has attempted to identify important risks, uncertainties and factors that could cause actual results to differ materially, there may be others that cause results not to be as anticipated, estimated or intended.
  • RIV Capital does not intend, and does not assume any obligation, to update this forward-looking information except as otherwise required by applicable law.

Lotus Reports Third Fiscal Quarter of 2021

Retrieved on: 
Friday, July 30, 2021
Lotus Cars, South Norfolk, Lotus Software, Effects of cannabis, Motor vehicles, Companies, Automotive industry

VANCOUVER, British Columbia, July 30, 2021 (GLOBE NEWSWIRE) -- Lotus Ventures Inc. (CSE: J) (OTC: LTTSF) (FRA: LV9) (Lotus, or the Company, or Lotus Cannabis Co.) a premium cannabis producer in Canada, today announced the results for the three and nine months ended May 31, 2021.

Key Points: 
  • VANCOUVER, British Columbia, July 30, 2021 (GLOBE NEWSWIRE) -- Lotus Ventures Inc. (CSE: J) (OTC: LTTSF) (FRA: LV9) (Lotus, or the Company, or Lotus Cannabis Co.) a premium cannabis producer in Canada, today announced the results for the three and nine months ended May 31, 2021.
  • The Company reported quarterly revenue of $1.43 million and $4.24 million for the nine months ended May 31, 2021.
  • The third quarter was also the fifth consecutive quarter where revenues continued to exceed $1.37 million.
  • The Company reported its fourth profitable quarter and net income of $208,893 or 14% of net revenue for the three-month period.

Khiron Welcomes Dr. Eduardo Faveret as Medical Director for Brazil

Retrieved on: 
Thursday, July 29, 2021
Psychoactive drugs, Health sciences, Herbalism, Medicinal plants, Cannabis smoking, Cannabis, Entheogens, Medical cannabis, Legality of cannabis, Effects of cannabis

Dr. Faveret is a prominent advocate for medical cannabis in Brazil and a leading prescriber in the country of more than 200 million people.

Key Points: 
  • Dr. Faveret is a prominent advocate for medical cannabis in Brazil and a leading prescriber in the country of more than 200 million people.
  • Dr. Faveret boasts a highly distinguished medical and academic career, as the founder and former medical director of the Epilepsy Center at the Paulo Niemeyer State Brain Institute in Rio de Janeiro.
  • Alvaro Torres, Khiron CEO and Director, commented: "We are thrilled to welcome Dr. Faveret to our team.
  • With over eight years' experience helping patients access medical cannabis, Dr. Faveret is a leading medical cannabis specialist in Brazil who shares our mission of improving patients' lives through medical cannabis.

Lantern Expands On-Demand Recreational Cannabis Delivery to Grand Rapids

Retrieved on: 
Thursday, July 29, 2021
Herbalism, Medicinal plants, Health sciences, Cannabis smoking, Psychoactive drugs, Medicine, Cannabis, Entheogens, Medical cannabis, Effects of cannabis, Draft:Verda

GRAND RAPIDS, Mich., July 29, 2021 /PRNewswire/ -- Lantern , the leading on-demand cannabis e-commerce marketplace and home delivery platform in the U.S., today launched on-demand recreational cannabis delivery in Grand Rapids, becoming the first marketplace to offer delivery in Michigan's second largest city.

Key Points: 
  • GRAND RAPIDS, Mich., July 29, 2021 /PRNewswire/ -- Lantern , the leading on-demand cannabis e-commerce marketplace and home delivery platform in the U.S., today launched on-demand recreational cannabis delivery in Grand Rapids, becoming the first marketplace to offer delivery in Michigan's second largest city.
  • Lantern has been serving Michigan consumers since October 2020 when it became the first platform to launch on-demand delivery in Detroit.
  • Recreational consumers in Grand Rapids can now order their favorite products and brands directly from LanternNow.com and receive their orders in 60 minutes or less.
  • Lantern is the leading cannabis e-commerce marketplace and delivery platform in the U.S. With the speed and convenience of on-demand delivery, Lantern partners with the best local dispensaries and cannabis brands to bring transparency, safety, and access to cannabis for both new and experienced consumers through intuitive, personalized shopping experiences.

PeakBirch Logic Announces the Acquisition of Stul Ltd

Retrieved on: 
Thursday, July 29, 2021
Psychoactive drugs, Cannabis smoking, Entheogens, Euphoriants, Medicinal plants, Cannabis, Effects of cannabis, Head shop, Manny Stul

Acquisition Accelerates Goal to Expand Cannabis Sales in the U.K. Market

Key Points: 
  • Acquisition Accelerates Goal to Expand Cannabis Sales in the U.K. Market
    PeakBirch announces the acquisition of Stul Ltd. and its brand Hot Box Herb, a leading Headshop in Chelmsford, Essex.
  • VANCOUVER, BC, July 29, 2021 /PRNewswire/ -PeakBirch Logic Inc. (CSE: PKB) (FSE: KYH2) (OTCQB: KTNNF) ("PeakBirch" or the "Company") is pleased to announce the closing of the acquisition (the "Acquisition") of Stul Ltd. ("Stul" or the "Seller"), located in London, United Kingdom.
  • As part of the Acquisition, PeakBirch acquired Hot Box Herb, a leading brick and mortar cannabis accessory shop (a headshop) and e-commerce website.
  • With the acquisition of Stul, PeakBirch will receive 350K GBP in working capital which includes approximately 150K GBP in inventory, including shisha, tobacco and pipes, cannabis accessories, high-end designer bongs, and CBD.

180 Life Sciences Announces Selection of Lead Synthetic CBD Analogue

Retrieved on: 
Wednesday, July 28, 2021
Medicinal plants, Psychoactive drugs, Health sciences, Entheogens, Euphoriants, Herbalism, Cannabis smoking, Medicine, Cannabis, Raphael Mechoulam, Medical cannabis, Effects of cannabis

MENLO PARK, Calif., July 28, 2021 (GLOBE NEWSWIRE) -- 180 Life Sciences Corp. (NASDAQ: ATNF) (180 Life Sciences or the Company), a clinical-stage biotechnology company focused on the development of novel drugs that fulfill unmet needs in inflammatory diseases, fibrosis and pain,announced today that it has selected a lead Synthetic CBD Analogue that is expected to move forward in clinical development for both inflammation and pain.

Key Points: 
  • MENLO PARK, Calif., July 28, 2021 (GLOBE NEWSWIRE) -- 180 Life Sciences Corp. (NASDAQ: ATNF) (180 Life Sciences or the Company), a clinical-stage biotechnology company focused on the development of novel drugs that fulfill unmet needs in inflammatory diseases, fibrosis and pain,announced today that it has selected a lead Synthetic CBD Analogue that is expected to move forward in clinical development for both inflammation and pain.
  • As part of a continuing collaboration since 1998 with the pioneer of cannabis chemistry, Raphi Mechoulam (Hebrew University, Jerusalem), Sir Marc Feldmanns (the Companys Co-Executive Chairman and Co-Founder) laboratory, and 180 Life Sciences scientists, identified the non-psychoactive CBD analogue as a lead molecule in the Companys SCA platform.
  • Dr. James Woody, 180 Life Sciences Chief Executive Officer, stated, We believe that our lead compound HUM-217, a CBD derivative generated by cannabis chemistry pioneer Prof Raphael Mechoulam, meets all the criteria desirable to advance to clinical development.
  • 180 Life Sciences is leading the research into solving one of the worlds biggest drivers of disease inflammation.

Colorado State University Launches CBD Veterinary Survey

Retrieved on: 
Wednesday, July 28, 2021
Psychoactive drugs, Entheogens, Cannabis smoking, Euphoriants, Medicinal plants, Health sciences, Effects of cannabis, Cannabis, Veterinarian, Colorado State University, Veterinary medicine

DENVER, July 28, 2021 /PRNewswire/ -- Colorado State University professors and principal investigators, Dr. Stephanie McGrath and Dr. Felix Duerr, are leading a survey of pet owners to help researchers and veterinarians understand consumer attitudes toward the use of CBD/cannabis products in veterinary patients.

Key Points: 
  • DENVER, July 28, 2021 /PRNewswire/ --Colorado State University professors and principal investigators, Dr. Stephanie McGrath and Dr. Felix Duerr, are leading a survey of pet owners to help researchers and veterinarians understand consumer attitudes toward the use of CBD/cannabis products in veterinary patients.
  • Nationally recognized for their extensive CBD research, McGrath and Duerr's latest CBD study will gather information on veterinary recommendations of CBD/cannabis products for their clients' pets.
  • The CBD veterinary research study is made possible through funding from Colorado based, RYTE CBD .
  • "CSU's College of Veterinary Medicine and Biomedical Sciences is a national leader in animal health research and treatment, and we are proud to support Dr. McGrath's and Dr. Duerr's research on possible veterinary CBD applications," said RYTE CBD CEO Eric White.

Collective Project Launches Lineup of Cannabis-Infused Craft Beverages

Retrieved on: 
Tuesday, July 27, 2021
Psychoactive drugs, Cannabis smoking, Cannabis, Entheogens, Herbalism, Cocktail, Tea, Juice, Effects of cannabis

Hamilton, Ontario, July 27, 2021 (GLOBE NEWSWIRE) -- Collective Project has developed a brand-new range of Cannabis-infused beverages now available at OCS.ca.

Key Points: 
  • Hamilton, Ontario, July 27, 2021 (GLOBE NEWSWIRE) -- Collective Project has developed a brand-new range of Cannabis-infused beverages now available at OCS.ca.
  • Collective Project beverage combines fresh juices, real botanicals and high-quality cannabis emulsions for an unparalleled flavour profile and drinking experience.
  • Collective Project teas and juices include a diverse portfolio of doses that may be suitable for a variety of consumers.
  • Made with real ingredients and an emulsion of 10mg THC & 10mg CBD
    Collective Project adds to Collective Arts growing lineup of over 150 annual beverage releases including craft beer, ready-to-drink cocktails and sparkling hard teas.